Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

Clinical trial NCT07762703 · NOT_YET_RECRUITING

Trial details

NCT number

NCT07762703

Sponsor

BreakBio Corp

Status

NOT_YET_RECRUITING

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2026-09-01

Primary completion

2030-09-01

Enrollment

10

View on ClinicalTrials.gov